TOVX
Theriva Biologics, Inc.
There isn't enough reported data to score TOVX yet.
TOVX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TOVX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
TOVX PE Valuation
TOVX has no meaningful PE right now: it lost money over the past year.
TOVX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect TOVX's losses to shrink, with revenue holding steady.
TOVX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$15.42 | +$17.39 |
| Q2 2025 | -$21.78 | +$8.97 |
| Q1 2025 | -$30.60 | -$2.10 |
| Q4 2024 | -$36.55 | -$8.05 |
| Q3 2024 | -$32.81 | +$4.69 |
| Q2 2024 | -$30.75 | +$10.25 |
| Q1 2024 | -$28.50 | +$11.75 |
| Q4 2023 | -$28.50 | +$11.75 |
TOVX is still losing money, but far less than before: $15.42 per share over the past year, against $245.00 at its worst in late 2019.
TOVX Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -709% | N/A |
TOVX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.9M | +$1.5M |
| Q1 2026 | -$2.5M | +$2.3M |
| Q4 2025 | -$2.9M | +$1.8M |
| Q3 2025 | -$4.3M | -$425K |
| Q4 2024 | -$4.7M | +$1.9M |
| Q3 2024 | -$3.9M | -$831K |
| Q4 2023 | -$6.6M | -$1.1M |
| Q3 2023 | -$3.1M | +$1.4M |
TOVX has burned cash in almost every quarter: −$13M over the past year, against −$20M the year before.
TOVX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +580% | +39.1M shares |
| 3 years | +7486% | +45.3M shares |
| 5 years | +60249% | +45.8M shares |
| Available history | +69696% | +45.8M shares |
TOVX has 46M diluted shares, up 580% from a year ago.
TOVX Net Leverage
TOVX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TOVX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 15.7 | Oversold |
TOVX's weekly RSI is 33 (neutral) and its Stochastic is 16 (oversold).
TOVX PE vs Healthcare Sector
TOVX has no meaningful PE right now: it lost money over the past year.
TOVX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.20 | 20% below |
| 20 week MA | $0.22 | 27% below |
| 50 week MA | $0.23 | 30% below |
| 100 week MA | $0.51 | 69% below |
| 200 week MA | $6.07 | 97% below |
TOVX is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
TOVX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.4 | $94.2 | -28% |
| 2021 | $94.2 | $82.9 | -12% |
| 2022 | $82.9 | $10.5 | -87% |
| 2023 | $10.5 | $10.8 | +2.4% |
| 2024 | $10.8 | $1.47 | -86% |
| 2025 | $1.47 | $0.19 | -87% |
| 2026 YTD | $0.19 | $0.16 | -16% |
TOVX has finished lower in five of the last six years. It's down 16% so far in 2026.